Key facts
- This page summarizes Third Rock Ventures IV, L.P.'s Form 4 filing for Magenta Therapeutics, Inc. (DNTH).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Feb 2023, 15:30.
Third Rock Ventures IV, L.P. - 07 Feb 2023 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- DNTH
- Reported as of
- 07 Feb 2023
- Net transaction value
- -$3,056,000
- SEC form
- 4
- Accepted by SEC
- 09 Feb 2023, 15:30:21 UTC
- Prior SEC filing
- 26 Aug 2021
- Next SEC filing
- 21 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Third Rock Ventures IV, L.P. filed Form 4 for Magenta Therapeutics, Inc. (DNTH) on 09 Feb 2023.
Change
- Previous filing in this sequence was filed on 26 Aug 2021.
- Current net transaction value: -$3,056,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MGTA
transaction
Common Stock
Sale
- Transaction value
- $1,826,000
- Shares
- -2,200,000
- Change %
- -33%
- Price
- $0.8300
- Shares after
- 4,558,204
- Date
- 07 Feb 2023
- Ownership
- Direct
- Footnotes
- F1, F2
MGTA
transaction
Common Stock
Sale
- Transaction value
- $1,230,000
- Shares
- -1,500,000
- Change %
- -33%
- Price
- $0.8200
- Shares after
- 3,058,204
- Date
- 08 Feb 2023
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Third Rock Ventures IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.808 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
Footnote F2
These shares are directly held by Third Rock Ventures IV, L.P. ("TRV IV"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
Footnote F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.801 to $0.893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).